14.70
Dyne Therapeutics Inc stock is traded at $14.70, with a volume of 506.48K.
It is up +0.25% in the last 24 hours and down -19.71% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$14.60
Open:
$14.8
24h Volume:
506.48K
Relative Volume:
0.21
Market Cap:
$2.42B
Revenue:
-
Net Income/Loss:
$-412.89M
P/E Ratio:
-3.8083
EPS:
-3.86
Net Cash Flow:
$-361.93M
1W Performance:
-9.03%
1M Performance:
-19.71%
6M Performance:
+10.55%
1Y Performance:
+23.10%
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
DYN
Dyne Therapeutics Inc
|
14.69 | 2.40B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.09 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.43 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
747.89 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.72 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
298.21 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Dyne Therapeutics, Inc. $DYN Shares Acquired by Vanguard Group Inc. - MarketBeat
Morgan Stanley Maintains 'Overweight' on DYN but Lowers Price Ta - GuruFocus
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Potential 142% Upside in the Biotech Arena - DirectorsTalk Interviews
Chardan Capital Maintains Buy Rating on Dyne Therapeutics (DYN) - GuruFocus
HC Wainwright & Co. Lowers Price Target for Dyne Therapeutics (D - GuruFocus
Decoding Dyne Therapeutics Inc (DYN): A Strategic SWOT Insight - GuruFocus
DYN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Overweight Maintained for Dyne Therapeutics (DYN) by Morgan Stanley March 2026 - Meyka
Raymond James reiterates Dyne Therapeutics stock rating on FDA pathway By Investing.com - Investing.com Canada
Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.6% After Earnings Miss - MarketBeat
Morgan Stanley cuts Dyne Therapeutics stock price target on model update - Investing.com Canada
Dyne’s Larger 2025 Loss And New Shelf Registration Might Change The Case For Investing In Dyne Therapeutics (DYN) - simplywall.st
Dyne Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Dyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Dyne Therapeutics Posts Wider Loss In Q4 - Nasdaq
Dyne Therapeutics (DYN) Beats Q4 EPS Expectations - GuruFocus
Dyne Therapeutics Q4 Net Loss Narrows - marketscreener.com
Dyne Therapeutics (DYN) Approaches Key Transformation Phase - GuruFocus
DYNE THERAPEUTICS ($DYN) Releases Q4 2025 Earnings - Quiver Quantitative
Dyne Therapeutics (NASDAQ:DYN) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Dyne Therapeutics (NASDAQ: DYN) pairs 2025 loss with pivotal DMD and DM1 milestones - Stock Titan
Dyne Therapeutics eyes 2027 Duchenne drug launch, backed by $1.1B cash - Stock Titan
Dyne Therapeutics 2025 10-K: $0 Revenue, Net Loss $446.2M - TradingView
Dyne Therapeutics (NASDAQ: DYN) advances FORCE-based neuromuscular pipeline - Stock Titan
DYNDyne Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Oppenheimer Upgrades Dyne Ahead of Avidity's Upcoming Trial Results - Intellectia AI
Dyne Therapeutics, Inc. $DYN Holdings Raised by JPMorgan Chase & Co. - MarketBeat
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sarepta CEO To Jump Ship After 'Tumultuous' Year - Benzinga
Dyne Announces Positive Results from DELIVER Trial for DMD at MDA Conference - Intellectia AI
Dyne Therapeutics earnings ahead: DMD filing timeline in focus - Investing.com Australia
Dyne Therapeutics to Participate in Upcoming Investor Conferences - Investing News Network
Biotech Dyne Therapeutics heads to three March investor conferences - Stock Titan
Dyne Therapeutics (DYN) Stock Analysis: Exploring a 153% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Price-Driven Insight from (DYN) for Rule-Based Strategy - Stock Traders Daily
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference - Sahm
Dyne Therapeutics (DYN) to Showcase Key Developments at 2026 MDA Conference - GuruFocus
Dyne Therapeutics to Showcase Positive Results from DELIVER Trial and Phase 3 Trial Design at 2026 MDA Clinical & Scientific Conference - Quiver Quantitative
New heart-lung data in rare muscle diseases: inside Dyne’s 2026 trial push - Stock Titan
Aberdeen Group plc Purchases 72,770 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Aug PostEarnings: Is Dyne Therapeutics Inc a turnaround storyBreakout Watch & Entry Point Confirmation Signals - baoquankhu1.vn
Dyne Therapeutics (DYN) to Release Earnings on Thursday - MarketBeat
Bullish Analyst Opinion on Dyne (DYNE) Follows Rare Disease Drug Progress in Japan - Finviz
VIX Spike: What is Dyne Therapeutics Incs 5 year growth outlookIPO Watch & Weekly Sector Rotation Insights - baoquankhu1.vn
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Exploring a 151% Upside Potential in Biotech - DirectorsTalk Interviews
Weekly Trades: Can Dyne Therapeutics Inc disrupt its industry2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry - Finviz
Dyne Therapeutics announces $300M proposed public offering - MSN
Can Dyne Therapeutics Inc. disrupt its industryWeekly Risk Summary & Daily Profit Focused Stock Screening - mfd.ru
Earnings Risk: Is Dyne Therapeutics Inc gaining market shareJuly 2025 Movers & Verified Momentum Stock Watchlist - baoquankhu1.vn
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):